Controversial Issues in the Treatment of Dyslipidemias in Patients with Diabetes Mellitus



Título del documento: Controversial Issues in the Treatment of Dyslipidemias in Patients with Diabetes Mellitus
Revista: Revista de investigación clínica
Base de datos: PERIÓDICA
Número de sistema: 000456907
ISSN: 0034-8376
Autores: 1
Instituciones: 1University of Munich, Medizinische Klinik IV - Grosshadern, Munich, Baviera. Alemania
Año:
Volumen: 70
Número: 5
Paginación: 237-243
País: México
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Patients with diabetes mellitus have an elevated cardiovascular risk. Lipid-lowering therapy is a successful strategy to prevent atherosclerotic events in these patients. Therefore, almost all professional societies recommend statin therapy for patients with diabetes under certain conditions. Despite this broad consensus, a number of controversial issues remain. Thus, it remains unclear in which patients the lipid parameters should be determined in the fasting state and in which postprandial values are sufficient. It is also an open issue whether all patients with diabetes should receive statin therapy and which goals should be achieved. While the benefit of statin-ezetimibe and statin-PCSK9-inhibition combinations has been shown in large outcome trials, results of outcome trials involving statins with triglyceride lowering drugs have been ambiguous. Thus, it is currently unclear which patients benefit from such combinations. Finally, the best strategy to address severe hypertriglyceridemia in patients with diabetes is unclear. This article discusses these issues and aims to provide help and information to practicing physicians taking care of patients with diabetes mellitus
Disciplinas: Medicina
Palabras clave: Endocrinología,
Metabolismo y nutrición,
Diabetes mellitus,
Dislipidemia,
Lipoproteínas de baja densidad,
Colesterol,
Riesgo cardiovascular
Keyword: Endocrinology,
Metabolism and nutrition,
Diabetes mellitus,
Dyslipidemia,
Low density lipoproteins,
Cholesterol,
Cardiovascular risk
Texto completo: https://www.medigraphic.com/pdfs/revinvcli/nn-2018/nn185e.pdf